Shopping Cart (0)
My Account

Shopping Cart
SELECTBIO Conferences Prognostic, Predictive, and POC: Biomarkers from Research to Clinic

Howard Federoff's Biography

Howard Federoff, Professor, Georgetown University Medical Center

As Executive Vice President for Health Sciences at Georgetown University and Executive Dean of the School of Medicine, Dr. Federoff is responsible for Georgetown University Medical Center (GUMC). He is a professor of Neurology and Neuroscience. Prior to Georgetown, he held appointments as Senior Associate Dean; Professor of Neurology, Medicine, Microbiology and Immunology; and Professor of Oncology and Genetics at the University of Rochester School of Medicine, and as Founding Director of the Center for Aging and Development Biology at the Aab Institute of Biomedical Sciences and Founding Division Chief of Molecular Medicine and Gene Therapy. He also served as Director of the University of Rochester’s Interdepartmental Neuroscience Program. Dr. Federoff’s research interests include gene therapy and neurodegenerative diseases. He has published greater than 250 peer review and invited articles and serves as a reviewer for many journals, and currently serves on the editorial boards of the Journal of Parkinson’s Disease, Open Genomics Journal and Journal of Experimental Neurology. Dr. Federoff served as Chair of the NIH Recombinant DNA Advisory Committee from 2007-2010. He Chairs the Gene Therapy Resource Program for NHLBI, was President of the American Society for Neural Therapy and Repair (2012-2013) and is President of the American Society for Experimental Neurotherapeutics. Dr. Federoff received MS, PhD, and MD degrees from the Albert Einstein College of Medicine, did his internship, residency, and clinical and research fellowships at Massachusetts General Hospital/Harvard Medical School, and practiced medicine at the Albert Einstein College of Medicine and University of Rochester. He is a Fellow of the AAAS and National Academy of Inventors.

Howard Federoff Image

Blood Biomarkers for Detection of Preclinical Alzheimer’s Disease

Friday, 16 January 2015 at 09:00

Add to Calendar ▼2015-01-16 09:00:002015-01-16 10:00:00Europe/LondonBlood Biomarkers for Detection of Preclinical Alzheimer’s DiseasePrognostic, Predictive, and POC: Biomarkers from Research to Clinic in San Diego, California, USASan Diego, California,

Plasma metabolites and exosome cargo identify antecedent memory impairment in older adults.  Community dwelling older adults (>75) enrolled in a longitudinal study wherein baseline cognitive battery and bloods were assessed. Subjects were followed with yearly cognitive assessments and blood tests. After several years a subset of individuals initially defined as cognitively normal, termed Converterpre become cognitively impaired, termed Converterpost, the latter meeting the diagnostic criteria of amnestic MCI or AD. Plasma analysis of analytes identified three different diagnostic panels that could robustly classify the Converterpre from cognitively normal subjects (NC).  The two metabolomics derived panels, 10 lipids and 17 metabolites produced classifier ROC AUCs of 0.96 and 1.00, respectively. When these panels were used in a validation subcohort they yielded ROC AUCs of 0.92 (10 lipids) and 0.99 (17 metabolites). An additional plasma diagnostic has been developed by examining four CNS pathogenic protein cargo analytes in presumptive neural exosomes. In our preliminary studies, these four analytes produce an ROC AUC of 1.00.  In our longitudinal cohort the phenoconversion from cognitively normal to cognitively impaired occurred with an average time of 2.1 years. These data indicate that highly sensitive and specific preclinical diagnostics are emerging and which may reorient therapeutics development to subjects with pre-symptomatic disease, i.e., secondary prevention trials.  Further work is ongoing to extend these observations and apply them to additional cohorts.

Add to Calendar ▼2015-01-15 00:00:002015-01-16 00:00:00Europe/LondonPrognostic, Predictive, and POC: Biomarkers from Research to ClinicPrognostic, Predictive, and POC: Biomarkers from Research to Clinic in San Diego, California, USASan Diego, California,